Free Trial

Vanda Pharmaceuticals (VNDA) Earnings Date, Estimates & Call Transcripts

Vanda Pharmaceuticals logo
$6.39 -1.05 (-14.11%)
Closing price 05/7/2026 04:00 PM Eastern
Extended Trading
$6.51 +0.12 (+1.88%)
As of 05:07 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Vanda Pharmaceuticals Earnings Summary

Vanda Pharmaceuticals released Q1 2026 earnings on May 6, 2026, reporting an EPS of -$0.82, which missed the consensus estimate of -$0.69 by $0.13. Quarterly revenue was reported to be $51.72 million, below analyst estimates of $54.98 million. With a trailing EPS of -$3.73, Vanda Pharmaceuticals' earnings are expected to grow next year, from ($2.18) to ($0.69) per share.

Latest Q1
Earnings Date
May. 6Estimated
Consensus EPS
(May. 6)
-$0.69
Actual EPS
(May. 6)
-$0.82 Missed By -$0.13
Actual Revenue
(May. 6)
$51.72M

Q1 2026 Earnings Resources

Get Vanda Pharmaceuticals Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vanda Pharmaceuticals and other key companies, straight to your inbox.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Estimated and Actual Earnings Data

VNDA Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

VNDA Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Vanda Pharmaceuticals Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateRevenue EstimateCompany Revenue Guidance
Q1 20261-$0.57-$0.57-$0.57
Q2 20261-$0.51-$0.51-$0.51
Q3 20261-$0.32-$0.32-$0.32
Q4 20261-$0.26-$0.26-$0.26
FY 2026 4 -$1.66 -$1.66 -$1.66
Q1 20271-$0.28-$0.28-$0.28
Q2 20271-$0.16-$0.16-$0.16
Q3 20271-$0.07-$0.07-$0.07
Q4 20271-$0.03-$0.03-$0.03

Vanda Pharmaceuticals Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
5/6/2026Q1 2026-$0.6880-$0.82 -$0.1320-$0.82$54.98M$51.72M
2/11/2026Q4 2025-$2.18-$2.39 -$0.21-$2.39$59.28M$57.22M
10/29/2025Q3 2025-$0.31-$0.38 -$0.07-$0.38$58.73M$56.26M
7/31/2025Q2 2025-$0.34-$0.46 -$0.12-$0.46$54.77M$52.59M
5/7/2025Q1 2025-$0.55-$0.50+$0.05-$0.50$45.13M$50.04M
2/13/2025Q4 2024-$0.14-$0.08+$0.06-$0.08$51.00M$53.19M
7/31/2024Q2 2024--$0.08--$0.08-$50.47M
5/8/2024Q1 2024$0.05-$0.07 -$0.12-$0.07$48.50M$47.46M

Data powered by Fiscal.ai.

Vanda Pharmaceuticals Earnings - Frequently Asked Questions

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earning data on Wednesday, May 6, 2026. Learn more on VNDA's earnings history.

Vanda Pharmaceuticals updated its FY 2026 earnings guidance on Wednesday, May, 6th. The company issued revenue guidance of $240.0 million-$290.0 million, compared to the consensus revenue estimate of $257.4 million.

In the previous quarter, Vanda Pharmaceuticals (NASDAQ:VNDA) missed the analysts' consensus estimate of ($0.69) by $0.13 with a reported earnings per share (EPS) of ($0.82). Learn more on analysts' earnings estimate vs. VNDA's actual earnings.

The conference call for Vanda Pharmaceuticals' latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for Vanda Pharmaceuticals' latest earnings report can be read online.
Read Transcript

Vanda Pharmaceuticals (NASDAQ:VNDA) has a recorded annual revenue of $216.10 million.

Vanda Pharmaceuticals (NASDAQ:VNDA) has a recorded net income of -$220.47 million. VNDA has generated -$3.73 earnings per share over the last four quarters.

Vanda Pharmaceuticals' earnings are expected to grow from ($2.18) per share to ($0.69) per share in the next year.


This page (NASDAQ:VNDA) was last updated on 5/8/2026 by MarketBeat.com Staff.
From Our Partners